KRAS and adenocarcinoma: Briefly, in the adenocarcinoma subtype, 26.2% (n = 195 out of 744) were KRAS-mutated, with p.Gly12Cys being the most frequent mutation identified in 9.4% (n = 70 out of 744), followed by p.Gly12Val in 6.2% (n = 46 out of 744).